Delcath Systems Showcases Hepatic Delivery System at SIR 2026 Meeting
Event summary
- Delcath Systems will present its Hepatic Delivery System at the SIR 2026 Annual Scientific Meeting in Toronto, April 11–15, 2026.
- Three presentations will feature clinical experiences with HEPZATO KIT and percutaneous hepatic perfusion (PHP).
- Presenters include Dr. Eric Wehrenberg-Klee (Massachusetts General Hospital), Dr. David Eschelman (Thomas Jefferson University), and Dr. Mustafa Ege Seker (University of Wisconsin).
- HEPZATO KIT is FDA-approved for treating metastatic uveal melanoma with liver involvement.
The big picture
Delcath Systems is positioning its Hepatic Delivery System as a key player in interventional oncology, particularly for liver-directed treatments. The SIR 2026 presentations could accelerate adoption among interventional radiologists, reinforcing its niche in treating metastatic uveal melanoma. The company’s ability to expand beyond this indication will be critical for long-term growth.
What we're watching
- Clinical Validation
- How the presentations at SIR 2026 will influence physician adoption of Delcath’s Hepatic Delivery System.
- Regulatory Expansion
- Whether Delcath can leverage FDA approval to expand indications beyond metastatic uveal melanoma.
- Commercial Execution
- The pace at which Delcath can scale its commercial operations following positive clinical feedback.
Related topics